Abstract
Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 125-127 |
| Number of pages | 3 |
| Journal | Kidney International |
| Volume | 78 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Jul 2010 |